Development of new comprehensive heart failure treatment that takes into account the underlying disease and the stage of the heart failure

点击翻译按钮获取中文摘要

We examined whether AMPK activation can modulate cardiac remodeling and inhibit the progression of heart failure in the canine myocardial infarction model and pacing induced decompensated heart failure, which is considered to be similar to human dilated cardiomyopathy and can be superimposed on translational study for human heart failure. Neither blood pressure nor heart rate differed between the groups with and without AICAR (AMPK activator) at 6 weeks after the onset of myocardial infarction or pacing-induced heart failure. Left ventricular ejection fraction increased, and mean pulmonary arterial pressure and pulmonary capillary wedge pressure decreased in the AICAR treated group compared with the untreated group. These effects were observed in both models, even after the onset of heart failure. Thus, we conclude that AMPK activation is an important novel therapeutic target in chronic heart failure.